Adults 18 to 65, any sex, with Post Traumatic Stress Disorder. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
PTSD Scale - Self-Report for DSM-5 (PDS-5; Foa et al., 2016)Primary· Last 1 Week
PTSD symptoms will be measured using the PTSD Scale - Self-Report for DSM-5 (PDS-5; Foa et al., 2016). Twenty items comprise the PTSD severity scale, with scores ranging from 0 to 80 and higher scores indicating higher PTSD severity. A total score is calculated.
Group
Value
95% CI
PTSD Lay-led Group Treatment Program
8.08
± 5.74
Patient Health Questionnaire-9 (PHQ-9; Kroenke, Spitzer, & Williams, 2001)Secondary· Last 1 Week
The PHQ-9 is a self-report measure of depression symptoms with each question rated from 0-3. Higher scores indicate greater depression severity, with scores ranging from 0 to 27.
Group
Value
95% CI
PTSD Lay-led Group Treatment Program
2.50
± 1.50
Somatic Symptoms Scale-8 (SSS-8; Gierk et al., 2014)Secondary· Last 1 Week
The Somatic Symptoms Scale is an 8 item version of the PHQ-15; self-report assessment of somatic symptoms (e.g., stomach pain, headaches, dizziness). The current version scored items on the original PHQ-15 scale from 0 to 2, with a range from 0 to 16.
Group
Value
95% CI
PTSD Lay-led Group Treatment Program
2.38
± 1.58
Quality of Well-being IndexSecondary· Last 1 Week
The WHO-5 Wellbeing Index (WHO-5; Bech, Olsen, Kjoller, \& Rasmussen, 2003) will be used to measure well-being. This five-item measure assesses emotional well-being on a 0-5 scale, with higher scores reflecting better well-being. Range of scores is from 0 to 25.
Group
Value
95% CI
PTSD Lay-led Group Treatment Program
19.38
± 2.48
Sponsor's own description
This study will examine the initial feasibility of a program called Islamic Trauma Healing by conducting a small feasibility study (N = 26) of Islamic Trauma Healing in Somalia on key targets of PTSD, depression, somatic symptoms, and quality of life. The hypothesis is that those in Islamic Trauma Healing will show a reduction of PTSD symptoms, depressive symptoms, and somatic symptoms and show improvement in quality of well-being. Feasibility will also be examined by examining at retention, satisfaction, and community feedback.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT05890482 — A Scalable, Community-based Program for War and Refugee Trauma
· NA
· unknown
NCT03502278 — A Lay-Led Intervention for War and Refugee Related Trauma
· NA
· completed
Other recruiting trials for Post Traumatic Stress Disorder
Currently open trials in the same condition.
NCT07485231 — Nitric Oxide (NO) and Endothelial Dysfunction in Women With PTSD
· NA
· recruiting
NCT07316088 — Determining the Potential for Efficacy of OTX-601 in Reducing PTSD Symptoms
· Phase 2
· recruiting
NCT07227337 — Being Safe, Healthy, And Positively Empowered (BSHAPE) Intervention Study
· NA
· recruiting
NCT06988787 — Multifaceted Intervention to Restore Resilience and Overcome Risk
· NA
· recruiting
NCT06740487 — Advanced Wireless Augmented Reality-Enhanced Exposure Therapy for Posttraumatic Stress Disorder
· NA
· recruiting
Other University of Washington trials
Trials by the same sponsor.
NCT07430852 — Inherited and Environmental Risks Acting on Body Weight
· NA
· not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc
· Phase 2
· not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn
· NA
· not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
· Phase 2
· not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle
· Phase 2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 21 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03761732.